Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study

Raimondi, Alessandra; Di Maio, Massimo; Morano, Federica; Corallo, Salvatore; Lonardi, Sara; Antoniotti, Carlotta; Rimassa, Lorenza; Sartore-Bianchi, Andrea; Tampellini, Marco; Ritorto, Giuliana; Murialdo, Roberto; Clavarezza, Matteo; Zaniboni, Alberto; Adamo, Vincenzo; Tomasello, Gianluca; Petrelli, Fausto; Antonuzzo, Lorenzo; Giordano, Monica; Cinieri, Saverio; Longarini, Raffaella; Bergamo, Francesca; Niger, Monica; Antista, Maria; Peverelli, Giorgia; De Braud, Filippo; Di Bartolomeo, Maria; Pietrantonio, Filippo

doi:10.1016/j.ejca.2020.04.048

Quality of life (QoL) patient-reported outcomes (PROs) data from pivotal first-line trials in metastatic colorectal cancer (mCRC) are poor. The Valentino study showed that de-escalation to single-agent panitumumab after 4-month induction with panitumumab-FOLFOX is inferior to panitumumab-5-FU/LV in patients with RAS wild-type mCRC, although slightly reducing toxicity. We report QoL, a secondary end-point.

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study / Raimondi, A., Di Maio, M., Morano, F., Corallo, S., Lonardi, S., Antoniotti, C., Rimassa, L., Sartore-Bianchi, A., Tampellini, M., Ritorto, G., Murialdo, R., Clavarezza, M., Zaniboni, A., Adamo, V., Tomasello, G., Petrelli, F., Antonuzzo, L., Giordano, M., Cinieri, S., Longarini, R., et al.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - STAMPA. - 135:(2020), pp. 230-239. [10.1016/j.ejca.2020.04.048]